Patients with Alzheimer's disease and psychosis often have a more severe course of illness, with higher incidence of caregiver burden and hospitalization. Differentiating this disorder from Alzheimer's disease uncomplicated by psychosis is key to maximizing more positive outcomes. More »

Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a More »